The board of directors of Nanologica AB (publ) has decided to withdraw the proposal for a new stock option program for management and employees that was presented in the notice to Nanologica’s Annual General Meeting on June 2, 2022.
The board of directors has decided to withdraw the proposal to await the outcome of the stock option programs that expire on July 1 this year. Depending on the outcome, a new stock option program may be proposed later this year.
“We want to encourage a broad ownership among management and employees in Nanologica as it can benefit all shareholders. In light of this, we have decided to await the outcome of the programs that expire in July this year in order to then decide whether and how a new program should be designed.”, the chairperson of the board Gisela Sitbon comments.
Nanologica currently has three active stock option programs.
In the stock option program 2020/22 for the board of directors, all 350,000 options were subscribed and allocated. In the stock option program 2020/22 for the management and employees, 569,949 of the total 698,577 options were subscribed and allocated. Each option entitles the holder to subscribe for one share in the company at a subscription price corresponding to SEK 18, during the period 1 July 2020 to 1 July 2022. Based on the existing number of shares, the dilution will be a maximum of approximately 3.2 percent if all options are exercised.
During the fourth quarter, the option program 2021/2024, which was resolved by the Annual General Meeting on May 27, 2021, was implemented. In the program, all of the 800,000 options were subscribed for. Each option entitles the holder to subscribe for one share in the company at a subscription price corresponding to SEK 45, during the period 1 April 2024 to 1 July 2024. Based on the existing number of shares, the dilution will be a maximum of approximately 2.8 percent if all options are exercised.
For further information, please contact:
Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface properties of silica particles, creating opportunities to develop unique products. Through the two business areas, Drug Development and Chromatography, the company strives towards increasing the accessibility of innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide drugs available to more patients in need, by lowering the cost of manufacturing. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung, to provide new treatment options for patients with lung diseases. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed for trade on Nasdaq Stockholm Main Market since March 29, 2022. For further information, please visit www.nanologica.com.
This press release in English is a translation of the original press release in Swedish. In case of any discrepancies, the press release in Swedish has precedence.